Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05465616

Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c

This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participants with HbA1c levels between 5.7-8.9% (inclusive) will be recruited and randomized into either the placebo or intervention group. The study duration for each participant will be approximately 90 days. At the beginning of the 90 days, the participant will complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to Viome. After the samples are analyzed, the participant will receive dietary recommendations (either personalized or USDA) and supplements (either personalized or placebo). The participant will follow the dietary recommendations and take the supplements for 90 days. At the end of the 90 days, the participant will once again complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to Viome for analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated informed consent form and medical release prior to any trial-specific procedures are performed
  • Females and males aged 18 years or older
  • Able to speak and read English
  • HbA1c between 5.7-8.9% (inclusive), tested within the past 30 days
  • Willing and able to visit a Quest Diagnostic Patient Service Center (PSC)
  • Willing and able to follow the trial instructions and Viome's Precision Nutrition Program
  • Willing and able to use a smartphone and Viome app.

Exclusion criteria

  • Antibiotic use within one month of the GI test
  • Gestation within previous 6 month
  • Current (or previous) use of medications that increase insulin (sulfonylureas, such as glimepiride, glipizide, glyburide, etc.)
  • Current (or previous) use of exogenous insulin (such as Tresiba, Lantus, Toujeo, Levemir, Humalog, Novolog, Apidra, Fiasp, etc.)
  • On a specific diet, such as ketogenic, for the purpose of reducing HbA1c and/or weight within the previous month
  • Taking diet pills
  • Allergy to an ingredient in the MH capsule or stick pack
  • Currently on an investigational product
  • Significant surgery or medical procedure planned
  • Diet or lifestyle change during the trial period, besides those appropriate for trial arm Has followed Viome nutritional recommendations (foods and/or supplements)

Treatment and study plan

Viome's Precision Nutrition Program (VPNP)

Dietary Supplement

Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.

Primary outcomes

  1. HbA1c Levels

    Time frame: 4 months

    HbA1c changes in individuals in the interventional arm compared to baseline measurement.

  2. Insulin Resistance

    Time frame: 4 months

    Change in fasting insulin levels in those in the interventional arm compared to baseline measurement.

Secondary outcomes

  1. BMI

    Time frame: 4 months

    Changes in BMI of individuals in the interventional arm compared to baseline measurement.

  2. Cholesterol

    Time frame: 4 months

    Changes in HDL, LDL, total cholesterol, and triglyceride levels of those in the interventional arm compared to baseline measurements.

  3. Waist to Hip Ratio

    Time frame: 4 months

    Changes in waist to hip ratio of those in the interventional group compared to baseline measurement.

  4. Cardiovascular Risk

    Time frame: 4 months

    Changes to 10 year cardiovascular risk score of those in the interventional arm compared to baseline score.

  5. Patient Health Questionnaire 9 (PHQ 9) Score

    Time frame: 4 months

    Changes in PHQ9 score of those in the interventional arm compared to baseline answers. The minimum PHQ 9 score is 0 and the maximum PHQ 9 score is 27. Higher scores indicate a worse outcome.

  6. General Anxiety Disorder - 7 Score

    Time frame: 4 months

    Changes in GAD7 score in those in the interventional arm compared to baseline assessment. The minimum score on GAD 7 is 0-4 indicating none to minimal anxiety and the maximum score is 15-21 indicating sever anxiety. Higher scores indicate a worse outcome.

  7. Species prevalence in stool, blood, and saliva

    Time frame: 4 months

    Changes in the prevalence of species in stool, blood, and saliva samples compared to baseline analysis.

  8. Fasting glucose

    Time frame: 4 months

    Fasting glucose changes in individuals in the interventional arm compared to baseline measurement.

Study contacts

Contact information is provided by the study sponsor or research team.

Momchilo Vuyisich

CONTACT

[email protected]

(425) 300-6933

Mory Mehrtash

CONTACT

[email protected]

(425) 300-6933

Sponsors and collaborators

Lead sponsor

Viome

Industry

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jul 20, 2022
Registry last updated
Jan 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.